Pemetrexed in second line treatment of non-small cell lung cancer - The portuguese experience
{{output}}
Until 2004, docetaxel in monotherapy was the standard for second-line treatment of non-small cell lung cancer (NSCLC). Pemetrexed (P) has shown similar activity in this setting with a better adverse event profile. In Portugal, it was introduced in October of 2... ...
